Stemnovate in vitro testing platform simulates the liver, heart and neuronal cell response to evaluate predictable and unpredictable toxins over the breadth of the genetically diverse human population. The processes are highly data-driven with high-resolution images, genomic profiles, biological information, molecular and metabolite profiles. The computational modelling can correlate, assimilate and connect the data more rapidly to help discover patterns.
We aim to automate the prediction of toxicity and that will be a game-changing technology for precision drug discovery.

Platform features

Stemnovate is capable of designing and manufacturing a bespoke fluidic component to enhance repeatability of complex cell culture.
As a company, we are able to quickly design, validate and manufacture prototypes and complex designs.
Once a methodology is optimised the process can be set for reproducibility and automation.

We support projects to achieve a higher standard of accuracy, evaluating biocompatibility and tolerance.

Stemnovate in vitro toxicology

Stemnovate in vitro toxicology assays use primary cells or induced pluripotent stem cell-derived cells such as heart, liver and neurons in controlled laboratory conditions to examine the toxic properties of compounds and mixtures.

We develop assays to examine the toxicity of xenobiotics at the cellular level replacing animal testing, where species differences often fail to represent human physiological responses.

Quality control

We provide various quality tests to evaluate the quality of cell products. The tests use advanced bioinformatics with gene and protein expression.

  1. Mycoplasma testing
  2. Human viruses (HIV-1, HIV-2, HBV, HCV)
  3. Animal species specific viruses
  4. Mycobacterium testing